Start with the scoreboard: the stock has cratered more than 90% since the 2018 listing, and among stocks on Brazil's flagship index this year it ranks at the very bottom. The pain has been relentless, with annual losses in each of the past five years ranging from 12% to 56%.
Legal pressure and operating costs are piling on. Lawsuits from customers have climbed in recent quarters, and Renato Jerusalmi, who helps run Riza Asset Management as a co-founder and oversees portfolios there, estimates those cases now represent a little over 3% of Hapvida's net revenue.
Last month, one of Brazil's best known equity managers labeled a long-running Hapvida position "the biggest investment mistake in our history." Only one analyst tracked by Bloomberg still recommends buying the shares. "It's the classic value trap," said Jerusalmi. "It looks cheap, and then it just keeps getting cheaper. Hapvida is that case taken to the extreme."
Hapvida's slide accelerated after its 2021 tie-up with NotreDame Intermédica. The deal created a company valued north of 110 billion reais ($21.4 billion) and broadened its footprint into Brazil's populous southeast. What looked ambitious at the time ended up squeezing profitability. The company struggled to serve a more affluent client base just as Brazil's interest rates climbed and inflation gnawed at margins.
On the numbers, operating performance has disappointed. EBITDA has come in below expectations in three of the last four reporting periods, including a 17% shortfall in the April to June quarter, based on Bloomberg data. Morada Capital's fund manager Murilo Arruda captured the backdrop: it is hard to rebuild margins "in a sector where medical inflation - driven by therapies, procedures, and higher utilization - outpaces general inflation."
A few minutes a day is enough to stay genuinely informed about your money. Join Market Briefs free and start tomorrow.
Rising costs leave Hapvida with two unappealing options: accept thinner margins or push through higher premiums. That second route is risky for a business whose core membership skews price sensitive in Brazil's northeast. As Jerusalmi put it, "Hapvida's biggest challenge today is pushing through price increases, and the company hasn't been able to do that." He added, "The question isn't just whether the it will be able to execute the price increases, but how much it will cost in terms of member churn."
Cash generation has not solved the balance sheet math. Much of the cash coming in is being consumed by higher costs rather than paying down the company's 5.4 billion reais of debt. "Hapvida still has a solid cash position," BTG analyst Samuel Alves wrote, but he warned that "the clock is ticking" and that "Persistent cash consumption is increasingly concerning." Hapvida declined to comment through a representative.
Hapvida is not alone. After a pandemic-era spree of deals and expansion, parts of Brazil's private healthcare industry are now in workout mode, with Kora Saude, Alliança Saude and Oncoclinicas all pursuing out-of-court restructurings.
For your money, the punchline is simple enough: if costs keep outpacing pricing power and cash keeps getting soaked up, earnings recovery gets pushed further out. With only one buy rating on the stock and worries that conditions could deteriorate from here, the setup is high risk. That does not tell you what to do, but it does frame what to track next: pricing execution without heavy member churn, stabilization in legal costs, a path to margin repair, and real progress on that debt stack.
